6,615 Shares in Harrow, Inc. (NASDAQ:HROW) Acquired by Maridea Wealth Management LLC

Maridea Wealth Management LLC acquired a new stake in Harrow, Inc. (NASDAQ:HROW) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 6,615 shares of the company’s stock, valued at approximately $222,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Woodmont Investment Counsel LLC raised its stake in shares of Harrow by 0.5% during the 4th quarter. Woodmont Investment Counsel LLC now owns 81,400 shares of the company’s stock worth $2,731,000 after purchasing an additional 445 shares in the last quarter. Swiss National Bank increased its holdings in Harrow by 1.0% in the fourth quarter. Swiss National Bank now owns 59,300 shares of the company’s stock worth $1,990,000 after buying an additional 600 shares during the last quarter. Quest Partners LLC acquired a new position in Harrow in the third quarter worth approximately $29,000. China Universal Asset Management Co. Ltd. raised its position in Harrow by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock valued at $253,000 after acquiring an additional 727 shares in the last quarter. Finally, HighTower Advisors LLC lifted its stake in Harrow by 13.8% in the fourth quarter. HighTower Advisors LLC now owns 10,127 shares of the company’s stock valued at $340,000 after acquiring an additional 1,227 shares during the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Trading Down 6.0 %

Shares of HROW stock opened at $26.21 on Friday. Harrow, Inc. has a 12 month low of $9.86 and a 12 month high of $59.23. The company has a market cap of $933.47 million, a PE ratio of -27.88 and a beta of 0.69. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The business’s 50 day moving average is $28.90 and its two-hundred day moving average is $37.99.

Harrow (NASDAQ:HROW) last posted its earnings results on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. The business had revenue of $66.83 million for the quarter, compared to analyst estimates of $66.01 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. Equities analysts predict that Harrow, Inc. will post -0.53 EPS for the current year.

Analysts Set New Price Targets

HROW has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and set a $57.00 price target on shares of Harrow in a research note on Tuesday, March 18th. B. Riley lowered their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.